William Blair analyst Brandon Vazquez has maintained their neutral stance on HSIC stock, giving a Hold rating on July 25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Hold rating due to a combination of factors surrounding Henry Schein’s current financial performance and future outlook. The company’s sales figures are consistent with expectations, but earnings per share (EPS) have fallen short by 8% compared to market predictions. Despite this, the full-year guidance for 2025 remains unchanged, emphasizing the need for strong execution in the latter half of the year to meet these targets.
Additionally, while the management has outlined potential growth in EPS for 2026, driven by strategic partnerships, the details of these collaborations are yet to be fully disclosed. With the stock currently trading at 13 times the projected 2026 EPS, Vazquez maintains a cautious stance, awaiting further updates in the upcoming quarters to reassess the potential for sustained valuation and share price increase.
According to TipRanks, Vazquez is an analyst with an average return of -2.9% and a 31.71% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Neogen, Elanco Animal Health, and PROCEPT BioRobotics.
In another report released on July 25, Stifel Nicolaus also downgraded the stock to a Hold with a $75.00 price target.